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LYMPHOID NEOPLASIA
WT1 mutations in T-ALL
Valeria Tosello,1 Marc R. Mansour,2 Kelly Barnes,1 Maddalena Paganin,3 Maria Luisa Sulis,1,4 Sarah Jenkinson,2
Christopher G. Allen,2 Rosemary E. Gale,2 David C. Linch,2 Teresa Palomero,1,5 Pedro Real,1,6 Vundavalli Murty,1
Xiaopan Yao,7 Susan M. Richards,8 Anthony Goldstone,9 Jacob Rowe,10 Giuseppe Basso,3 Peter H. Wiernik,11,12
Elisabeth Paietta,11,12 Rob Pieters,13,14 Martin Horstmann,15,16 Jules P. P. Meijerink,13 and Adolfo A. Ferrando1,4,5
1Institute for Cancer Genetics, Columbia University, New York, NY; 2Cancer Institute, Department of Haematology, University College London, London,
United Kingdom; 3Hemato-Oncology Laboratory, Department of Pediatrics, University of Padua, Padua, Italy; Departments of 4Pediatrics and 5Pathology,
Columbia University Medical Center, New York, NY; 6Andalusian Stem Cell Bank, Centro de Investigacion Biomedica, Granada, Spain; 7Department of
Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA; 8Clinical Trial Service Unit, Oxford, United Kingdom; 9University College
London Hospitals, London, United Kingdom; 10Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel; 11Montefiore Medical
Center North, Bronx, NY; 12New York Medical College, New York, NY; 13Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s
Hospital, Rotterdam, The Netherlands; 14Dutch Childhood Oncology Group, The Hague, The Netherlands; 15Clinic for Pediatric Hematology and Oncology,
University Hospital Hamburg-Eppendorf, Hamburg, Germany; and 16German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia,
Hamburg, Germany
The molecular mechanisms involved in
disease progression and relapse in T-
cell acute lymphoblastic leukemia (T-
ALL) are poorly understood. We used
single nucleotide polymorphism array
analysis to analyze paired diagnostic
and relapsed T-ALL samples to identify
recurrent genetic alterations in T-ALL.
This analysis showed that diagnosis
and relapsed cases have common ge-
netic alterations, but also that relapsed
samples frequently lose chromosomal
markers present at diagnosis, suggest-
ing that relapsed T-ALL emerges from
an ancestral clone different from the
major leukemic population at diagnosis.
In addition, we identified deletions and
associated mutations in the WT1 tumor
suppressor gene in 2 of 9 samples.
Subsequent analysis showed WT1 muta-
tions in 28 of 211 (13.2%) of pediatric
and 10 of 85 (11.7%) of adult T-ALL
cases. WT1 mutations present in T-ALL
are predominantly heterozygous frame-
shift mutations resulting in truncation
of the C-terminal zinc finger domains of
this transcription factor. WT1 mutations
are most prominently found in T-ALL
cases with aberrant rearrangements of
the oncogenic TLX1, TLX3, and HOXA
transcription factor oncogenes. Sur-
vival analysis demonstrated that WT1
mutations do not confer adverse progno-
sis in pediatric and adult T-ALL. Overall,
these results identify the presence of
WT1 mutations as a recurrent genetic
alteration in T-ALL. (Blood. 2009;114:
1038-1045)
Introduction
T-lineage acute lymphoblastic leukemia (T-ALL) accounts for
10% to 15% of pediatric and 25% of adult ALL cases.1 Once
associated with a dismal prognosis, the introduction of intensive
combination chemotherapy protocols has led to remarkable
improvements in survival for this disease. Thus, more than 70%
of children and 50% of adult T-ALL patients achieve long-
lasting complete remissions.2 However, in contrast with the
favorable response to therapy in patients at diagnosis, the
prognosis of T-ALL patients with relapsed leukemia remains
poor, underscoring the need to identify molecular mechanisms
responsible for disease progression and to develop more effec-
tive antileukemic drugs active against relapsed T-ALL.
WT1 was originally identified as a tumor suppressor gene in
patients with the WAGR (Wilms tumor, aniridia, genitourinary
abnormalities, mental retardation) tumor predisposition syn-
drome, caused by inherited germline deletions in the chromo-
somal band 11p13.3 Germline mutations in WT1 are also present
in patients affected with the Denys-Drash syndrome (DDS), a
related tumor predisposition syndrome characterized by
pseudohermaphroditism, nephropathy, genital abnormalities,
and an increased risk of Wilms tumors.4 Moreover, biallelic
somatic mutations in WT1 account for 15% of sporadic Wilms
tumors.5 In addition to its prominent role in the pathogenesis of
Wilms tumors, WT1 mutations have been reported in 10% of
cases of acute myeloid leukemia (AML), 20% of biphenotypic
leukemias, and sporadic cases of T-ALL.6-9
In this study, we aimed to characterize the mechanisms of
disease progression and relapse in T-ALL via single nucleotide
polymorphism (SNP) array analysis of paired diagnostic and
relapsed T-ALL samples. Our results show a remarkable lack of
genomic instability in most high-risk T-ALL cases during
progression from diagnosis to relapse. In addition, we identified
the presence of recurrent chromosomal deletions involving the
WT1 locus in T-ALL. Subsequent mutation analysis revealed the
presence of WT1 mutations in approximately 10% of pediatric
and adult T-ALL samples at diagnosis. WT1 mutations in T-ALL
primarily consist of heterozygous frameshift insertions and
deletions encoding truncated proteins devoid of the C-terminal
zinc finger domains of WT1. Notably, WT1 mutations were
characteristically associated with aberrant expression of the
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TLX1, TLX3, and HOXA transcription factor oncogenes. These
results identify WT1 mutations as a recurrent genetic abnormal-
ity associated with aberrant HOX gene expression in T-ALL.
Methods
Patient samples and cell lines
Leukemic DNA and cryopreserved lymphoblast samples were provided by
collaborating institutions in the United States (Eastern Cooperative Oncol-
ogy Group [ECOG], Pediatric Oncology Group), United Kingdom (Medi-
cal Research Council [MRC]), The Netherlands (Dutch Childhood Oncol-
ogy Group [DCOG]), Germany (German Cooperative Study Group for
Childhood Acute Lymphoblastic Leukemia [COALL]), and Italy (Hemato-
Oncology Laboratory, Department of Pediatrics, University of Padua,
Padua, Italy). All samples were collected in clinical trials with informed
consent and under the supervision of the Institutional Review Board
committees of all participating institutions. Consent was obtained from all
patients at trial entry according to the Declaration of Helsinki. T-cell
phenotype was confirmed by flow cytometry.
CCRF-CEM, Jurkat, RPMI8402, and PF382 were obtained from ATCC.
The P12-ICHIKAWA, ALL-SIL, and HPB-ALL cell lines were from the
DSMZ repository. KOPTK1 and DND41 cell lines were a gift from Dr A. T.
Look (Dana-Farber Cancer Institute). The CUTLL1 has been described
before.10 T-ALL cell lines were cultured in RPMI 1640 media supplemented
with 10% fetal bovine serum, 100 U/mL penicillin G, and 100 g/mL
streptomycin at 37°C in a humidified atmosphere less than 5% CO2. HeLa
and 293T cells were grown in Dulbecco modified Eagle medium supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin G, and
100g/mL streptomycin at 37°C in a humidified atmosphere less than 5% CO2.
SNP array analysis
DNA samples from pediatric T-ALL patients (n  9) obtained at diagnosis,
remission, and relapse were analyzed with the GeneChip Human Mapping
250K Sty Array (Affymetrix), which contains 23 800 SNPs. Copy number
and loss of heterozygosity (LOH) analysis was performed with dCHIP.
Probe intensity data for each array were normalized to a baseline array with
median signal intensity using the “invariant set” model, as previously
described.11 We used matched remission samples as a reference for copy
number estimation and LOH analysis. LOH was analyzed using a Hidden
Markov Model in dChip and an inferred LOH call threshold of 0.5. SNP
array data were deposited in the Gene Expression Omnibus (GEO; National
Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/geo/)
under accession no. GSE15931.
Karyotype and fluorescence in situ hybridization analysis
Interphase preparations from T-ALL cells obtained at diagnosis were
subjected to fluorescence in situ hybridization (FISH) analysis using PAC
clones RP11-299P16, RP1-259N9, and RP1-74J1. DNA from BACS
RP11-299P16 and RP1-259N9 located telomeric and centromeric to the
WT1 locus, respectively, were labeled using spectrum orange dUTP
fluorochrome (Vysis). BAC RP1-74J1, expanding the WT1 gene, was
labeled with spectrum green-dUTP fluorochrome (Vysis). FISH was
performed by standard methods as previously described.10 Hybridization
signals were scored on at least 500 interphase nuclei on 4,6-diamidino-2-
phenylindole-stained slides using the Cytovision Imaging system attached
to a Nikon Eclipse 600 microscope (Applied Imaging).
Molecular characterization of T-ALL samples
WT1 mutations were analyzed by polymerase chain reaction (PCR)
amplification of WT1 exons 1 to 10 followed by direct bidirectional DNA
sequencing. DNA samples from T-ALL patients enrolled in the UKALLXII
protocol were screened for mutations by denaturing high performance
liquid chromatography (DHPLC) using the WAVE system (Transgenomic
Inc) before DNA sequencing. Briefly, WT1 exons 2 to 10 were amplified by
PCR using the proof-reading enzyme Optimase (Transgenomic Inc) accord-
ing to manufacturer’s specifications, whereas exon 1 was amplified using
BioTAQ DNA polymerase (Bioline). For exons 1 to 3, 1 M betaine was
added to the PCR buffer to enhance the amplification of these high GC-rich
amplicons. Samples with abnormal DHPLC mobility profiles were selected
for bidirectional DNA sequence analysis. To ensure adequate detection of
hemizygous or homozygous mutations by DHPLC, each PCR product was
combined with an amplicon generated from a known WT1-wild-type
template.
NOTCH1 mutation analysis was performed by PCR amplification and
direct DNA sequencing of NOTCH1 exons 26, 27, 28, and 34 as previously
described.12,13 FBXW7 mutation analysis was performed by PCR amplifica-
tion and direct DNA sequencing of FBXW7 exons 9 and 10 as previously
described.14
Expression analysis of T-ALL transcription factor oncogenes, including
TLX1/HOX11, TLX3/HOX11L2, HOXA9, TAL1, LMO1, LMO2, SET-NUP,
MLL-ENL, and CALM-AF10, has been described before.15,16
Methylation analysis of the WT1 locus
Analysis of the methylation status of regulatory sequences in the WT1 locus
was performed by combined bisulfite restriction analysis.17 Genomic DNA
was bisulfite converted using the CpGenome DNA Modification kit
(Chemicon International) and amplified by PCR using primers WT1
bisulfite FW 5-AATTTTTAGGTAAGGAGAAG-3 and WT1 bisulfite RV
5-CACATAAATTTAACTAAAAAACT-3. Each PCR reaction contained
150 ng of bisulfate converted DNA, 60 pmol of each amplification primer,
10 nM dNTPs, 2.5 U of Taq polymerase (AmpliTaq gold, Applied
Biosystems), 5 L of 10  PCR Gold Buffer and PCR boost buffer
(Biomatrica) up to a total volume of 50 L. PCR amplification reactions
consisted of an initial denaturing step of 10 minutes at 95°C followed by
35 cycles of 30 seconds at 96°C, 30 seconds at 52°C, and 30 seconds at
72°C, plus a final elongation step of 10 minutes at 72°C. PCR products were
purified using the QIAquick Gel extraction Kit (QIAGEN), digested with
the BstuI restriction enzyme overnight at 60°C and subsequently analyzed
by gel electrophoresis.
Statistical analysis
Therapeutic outcome was analyzed in pediatric patients treated in DCOG
(n  72) and COALL (n  74) trials and in adult T-ALL cases treated in the
UKALLXII/ECOG2993 (n  85) protocols according to overall survival
and event-free survival. Kaplan-Meier curves were used to assess survival,
and differences between groups compared by the log-rank test.
Results
Genetic alterations in diagnostic and relapsed T-ALL
Recent studies have illustrated the power of SNP array-based copy
number analysis to identify important cancer-related genes associ-
ated with the pathogenesis of pediatric and adult acute lymphoblas-
tic leukemia.18-20 To analyze genomic alterations involved in the
pathogenesis of high-risk T-ALL and chromosomal changes associ-
ated with disease progression at relapse, we analyzed matched
diagnostic, remission, and relapsed DNA samples from 9 pediatric
T-ALL patients using Affymetrix 250K Sty SNP arrays. This
analysis demonstrated the presence of known recurrent chromo-
somal alterations associated with the pathogenesis of T-ALL in
each of the cases at diagnosis (Table 1). Most prominently, 6 of
9 cases (samples IId,r; IIId,r; Vd,r; VId,r; VIId,r; and VIIId,r)
showed homozygous deletions in the short arm of chromosome
9 centered on band 9p21, which result in loss of the CDKN2A/
p16INK4A and p14ARF tumor suppressor genes. Similarly, 2 pa-
tients (samples IIId and IVd) showed discrete deletions at chromo-
some 4q31.2-31.3, with a common deleted region centered on
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FBXW7, a tumor suppressor gene encoding an F-box protein respon-
sible for the proteasomal degradation of several oncoproteins involved
in the pathogenesis of T-ALL, including NOTCH1, c-MYC, and
mTOR.21 Larger deletions in chromosome regions 5q23.3-32 and
6q13-16.3, previously described as commonly deleted in T-ALL, were
detected in 2 of 9 (22%; samples IVd and IXd) and 3 of 9 (33%; samples
Id, VIr and VIId,r) patients, respectively. In addition, we observed a
focal area of amplification followed by a small deletion in chromosome
band 9q34 in one patient (samples Vd,r). This pattern of amplification
and deletion corresponds to the rearrangement and amplification of the
NUP214 and ABL1 loci to generate the NUP214-ABL1 fusion oncogene
present in 5% of T-ALLs.22 In addition to previously described
chromosomal alterations, our analysis demonstrated several additional
genetic lesions, including focal deletions at chromosome bands 7p21.3
(sample VIIIr), 10q26 (sample IVd), 14q31.1-31.2 (samples IXd,r),
14q32.2 (sample Vd,r), and 22q11.2 (samples VId,r) as well as broader
areas of deletion and genetic amplification (Table 1). Notably, with the
exception of patient VIII, whose tumor cells acquired 4 new areas of
deletion at the time of relapse, all other relapsed T-ALL samples showed
none or only one new chromosomal alteration gained during disease
progression. Overall, these results show that that acquisition of overall
genomic instability does not seem to be a driver mutagenic effect
contributing to relapse in T-ALL.
Although most of the chromosomal alterations identified in our
SNP array analysis were nonrecurrent, we noted that a region of
hemizygous deletion and LOH in chromosome band 11p13 found
in one of our patients (patient V) was overlapping with a weak area
of LOH present in a second T-ALL sample. Notably, the overlap
between these 2 alterations corresponded to the WT1 tumor
suppressor gene (Figure 1A). These results were confirmed and
extended via 2-color FISH analysis using a set of BAC clones
overlapping and flanking the WT1 locus (Figure 1B). Notably, this
analysis confirmed the loss of one copy of WT1 in 80% of the
nuclei in the T-ALL sample showing copy number loss and LOH in
11p13 in our SNP array analysis. In addition, this analysis revealed
a hemizygous deletion of WT1 in 39% of the nuclei in patient I at
diagnosis (Figure 1C). This subclonal deletion corresponds to the
detection of a focal region of weak LOH centered on the WT1 locus
without detectable copy number loss in the SNP array analysis in
this sample. Subsequent mutation analysis of WT1 in these patients
revealed frameshift mutations in exon 7 of WT1 in each of these
2 samples (Figure 1B-C), demonstrating that the LOH in this
case also results from an heterozygous deletion centered at the
WT1 locus.
Frequency and types of WT1 mutations in T-ALL
To address the actual prevalence and potential significance of WT1
mutations in T-ALL, we extended our mutation analysis of WT1 to
a panel of 294 primary T-ALL samples and 10 T-ALL cell lines.
This analysis demonstrated the presence of WT1 mutations in 28 of
211 (13.2%) pediatric and in 10 of 85 (11.7%) adult T-ALLs
(supplemental Tables 1-2, available on the Blood website; see the
Supplemental Materials link at the top of the online article). The
Table 1. Chromosomal abnormalities identified in T-ALL by SNP array analysis
Cases Gain/loss Chromosome Cytogenetic location Size, Mb No. of genes Candidate genes
VIIId,r Loss 1 p21.1-31.1 28 50 LMO4
VIIId,r Loss 1 p13.1-2 2.8 30
IIIr Loss 1 q32.3-44 35 50 WNT9A
IVd Loss 2 q21.1-31.2 20 50 TANK
IVd Loss 3 q12.1-21.3 34 50 mir-198
VIIIr Loss 3 q26.3-27.1 8.6 50 SOX2
IXd Loss 4 q21.1 0.06 0
IIId, IVd Loss 4 q31.2-31.3* 1 5 FBXW7
IVd, IXd Loss 5 q23.3-32* 16 50 CTNNA1
Id, VIr, VIId,r Loss 6 q13-16.3* 27 50
VIIId Gain 6 q15-27 84 50
VIIIr Loss 7 p11.2-12.3 7.5 20 IKZF1
VIIIr Loss 7 p21.3 1.6 3
VIIIr Loss 7 q31.3 0.8 4
VIIId Gain 8 p11.2-23 43 50
IId,r; IIId,r; Vd,r; VId,r;
VIId,r; VIIId,r
Loss 9 p21.3* 0.16 2 p16/INK4A; p14/ARF
Vd,r Gain 9 q34.12 0.6 2 NUP214-ABL1
Vd,r Loss 9 q34.13 0.5 6
VIIId,r Gain 9 q22.2-34.3 39 50
IVd Loss 10 q26.2 1.5 1 MGMT
Vd,r Loss 11 p13-14.1 2.8 18 WT1, PAX6
Id, IVd, IXd Loss 12 p12.3-13.31* 10 50 ETV6, CDKN1B, BCL2L14
Id Gain 14 q13.1-21.3 25 50
Id; VIIId,r Loss 14 q23.1* 1.5 10
Id; VIIId,r Loss 14 q23.2* 1.8 8
Id; VIIId,r Loss 14 q24.4-24.3* 6.3 50
Id; Vd,r; VIIId,r Loss 14 q32.1* 2.2 20
Vd,r Loss 14 q32.2 1.1 6
IXd,r Loss 14 q31.1-1.2 1 3 BCL11B
IXd,r Gain 14 q32.1-3 17 50 TRAF3, DICER1
IXd,r Gain 22 q12.3-13.3 48.5 50 WNT7B, CERK
VId,r Loss 22 q11.2 0.2 1 VPREB1
d indicates diagnostic samples; and r, relapse samples.
*Common minimally deleted regions are indicated.
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WT1 gene encompasses 10 exons encoding an N-terminal proline
and glutamine-rich domain (exons 1-6) involved in transcriptional
regulation followed by 4 C-terminal Kruppel-like DNA-binding
zinc fingers (exons 7-10).23 WT1 mutations found in T-ALL were
primarily frameshift insertions and deletions and occasional non-
sense point mutations located in exons 7 (30 of 38) and 8 (1 of 38),
which encode prematurely truncated WT1 proteins devoid of the
C-terminal zinc finger domains (Figure 2A-C). Splice donor
mutations in exons 1 and 7 were found in one T-ALL sample each
(Figure 2A,D). Additional frameshift mutations predicted to en-
code N-terminal truncations in WT1 were detected in exons 1
(4 cases) and 2 (1 case; Figure 2A,E). Two extra cases harbored
missense mutations in codon 462 (R462Q and R462P) located in
exon 9, which encodes the third zinc finger of the WT1 protein
(Figure 2A,F). The functional relevance of these alleles is high-
lighted by a related WT1 mutation, R462W, which has been
described as the most frequent genetic abnormality in patients with
DDS.24 Notably, the R462W mutation has also been identified in a
sporadic Wilms tumor sample and is predicted to impair the
DNA-binding activity of WT1.25 Three additional WT1 mutations
were identified in the CCRF-CEM, RPMI8402, and ALL-SIL cell
lines. CCRF-CEM and RPMI8402 cells showed 2 heterozygous
nonsense point mutations in exon 1 of WT1 encoding truncated
proteins of 115 and 188 amino acids, respectively, whereas the
ALL-SIL cell line harbored a heterozygous frameshift mutation in
exon 3, encoding a truncated WT1 protein of 293 amino acids
(supplemental Table 3). Analysis of paired leukemic and remission
DNA samples in 10 primary T-ALL cases showed loss of the WT1
mutant allele at remission, demonstrating that WT1 mutations are
somatically acquired in the leukemic clone (data not shown). In
addition to these well-defined WT1 mutations, we also detected
additional nonsynonymous nucleotide substitutions located in exon
1 in 4 T-ALL samples for which no remission DNA was available
(supplemental Table 4). Each of these alleles, none of which has
been described before, represents 0.002% of the chromosomes
analyzed in this study and may constitute somatic mutations or as
yet unreported private polymorphisms in the WT1 gene.
Although our analysis of WT1 mutations in T-ALL was guided
by the identification of WT1 deletions in our SNP array and FISH
analysis, 32 of 38 (84%) of the WT1 mutations identified in our
series showed retention of the wild-type allele. Consistently, FISH
analysis of 5 T-ALL samples harboring frameshift mutations in
WT1 demonstrated the absence of deletions or translocations in
11p13 involving the WT1-wild-type allele. Notably, each of the
2 T-ALL cases harboring a R462 WT1 missense mutation showed
complete inactivation of WT1 via loss of the WT1-wild-type allele
in the case of the R462P mutation or the result of an associated
frameshift mutation in exon 7 in the case of the R462Q sample
(Figure 2F; supplemental Table 1).
Mutation analysis of 10 paired diagnostic and relapsed T-ALL
samples showed that WT1 mutations were present both at diagnosis and
relapse in 5 cases (supplemental Table 5). Interestingly, we noted that in
one sample the signal of the DNAsequence corresponding to the mutant
WT1 allele was weaker than that of the corresponding wild-type allele at
diagnosis, with both alleles becoming equally abundant at relapse. In
addition, in 1 additional sample, the WT1 mutation was present only in
the relapse sample. Notably, in the 4 remaining sample pairs, we
observed evidence of WT1 mutations only at diagnosis (supplemental
Table 5).
Figure 1. Hemizygous deletion of WT1 in T-ALL. (A) Chromosome 11
ideogram and copy number (top) and LOH analysis (bottom) of paired
diagnostic (squares), relapsed (triangles), and remission (circles) T-ALL
samples. Flanking SNPs and genes included in these alterations are
indicated. Roman numbers identify individual patients. (B) FISH and
mutation analysis of WT1 in diagnostic sample V. (C) FISH and mutation
analysis of WT1 in diagnostic sample I. A chromosome 11 centromeric
probe is shown in blue. An intact WT1 locus is marked by an orange signal
from a WT1 BAC clone labeled in green and BAC clones telomeric and
centromeric to WT1 labeled in red. Arrows indicate nuclei with hemizygous
deletions of WT1. DNA sequence chromatograms focus in the WT1 exon 7
sequences containing frameshift mutations of WT1 in each of these
samples. Note that, although areas of LOH are marked across diagnostic,
remission, and relapsed samples, this corresponds to genetic lesions
present in diagnostic and/or relapsed samples compared with the corre-
sponding normal remission DNA.
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The development of Wilms tumors in patients with WARG syn-
drome, who harbor germline deletions of the WT1 locus, is invariably
associated with mutational loss of the second WT1 allele.26 However,
32 of 38 (84%) of the WT1 mutations found in our T-ALL series were
heterozygous, suggesting that epigenetic mechanisms could account for
the inactivation of the second copy of this tumor suppressor gene in
T-cell lymphoblasts. To test this hypothesis, we performed DNA
methylation analysis of regulatory sequences in the WT1 promoter using
a combined bisulfite restriction analysis assay. Notably, this analysis
failed to detect any significant methylation in the WT1 locus in
WT1-wild-type (n 6) and mutated (n 6) T-ALL samples (data not
shown). Consistently, direct sequence analysis of reverse-transcribed
PCR-amplified WT1 transcripts in 2 primary T-ALL samples harboring
truncating mutations in WT1 with available cDNA demonstrated
biallelic expression of both the wild-type and mutant alleles of WT1
(data not shown). Overall, only 3 WT1 mutations found in our series
were homozygous, with 3 additional cases showing compound heterozy-
gous WT1 mutations.
Association of WT1 mutations with expression of TLX1, TLX3,
and HOXA oncogenes
The malignant transformation of T-cell progenitors requires the
cooperative action of different oncogenic pathways. Most promi-
nently, aberrant activation of NOTCH signaling resulting from
activating mutations in NOTCH1 or mutational loss of FBXW7 is
found in more than 60% of T-ALL cases.12,14,27-29 In addition,
aberrant expression of transcription factor oncogenes, such as
TAL1, LMO1, LMO2, HOXA, TLX1, and TLX3, plays a major role
in the pathogenesis of T-ALL and defines distinct molecular groups
with prognostic significance.15,30-33
Mutation analysis of NOTCH1 and FBXW7 in 85 adult and
37 pediatric T-ALLs showed a similar incidence of these NOTCH-
activating lesions in WT1-wild-type (63 of 102 [61.7%] for NOTCH1
and 19 of 102 [18.6%] for FBXW7) and WT1 mutated (11 of 20 [55%]
for NOTCH1 and 5 of 20 [25%] for FBXW7) T-ALL cases (Fisher exact
test: P .62 for NOTCH1 and P .54 for FBXW7). In contrast,
analysis of associated genomic lesions associated with activation of
T-ALL transcription factor oncogenes in 127 pediatric T-ALL patients
showed that WT1 mutations were associated with genetic rearrange-
ments resulting in oncogenic activation of HOX genes. Thus, 8 of
13 WT1 mutant cases had an associated TLX3/ HOX11L2 translocation
(Fisher exact test: P .001). In addition, 1 patient had a TLX1/HOX11
translocation and 2 patients demonstrated aberrant activation of HOXA
genes because of the presence of inv(7)(p15q34), which involves the
HOXA and TCRB loci32 (1 patient), or because of the SET-NUP214
fusion associated with the del(9)(q34.11q34.13).33 Overall, 11 of
Figure 2. Somatic mutations in WT1 in T-ALL. (A) Schematic
representation of WT1 mutations identified in primary T-ALL samples.
(B-F) DNA sequence chromatograms showing representative ex-
amples of different mutations in WT1. (B) Frameshift truncating
mutation in exon 7 of WT1. (C) Nonsense point mutation in exon 7 of
WT1. (D) Acceptor site mutation affecting exon 7 of WT1.
(E) Frameshift truncating mutation in exon 1 of WT1. (F) Missense
mutations involving R462 in the DNA-binding domain of WT1.
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13 (85%) WT1 mutant cases showed aberrant expression of oncogenic
HOX factor gene. In 1 additional patient, the WT1 mutation was found in
association with an LMO2 translocation, whereas for 2 other patients no
specific translocations were identified.
Prognostic impact of WT1 mutations in T-ALL
Analysis of the prognostic impact of WT1 mutations in AMLs has
recently demonstrated that AML cases harboring genetic lesions in
WT1 have a poor prognosis.34,35 To analyze whether WT1 mutations
are also associated with an adverse clinical outcome in T-ALL, we
performed survival analysis in pediatric and adult T-ALL cases.
We investigated the presence of WT1 mutations in 2 indepen-
dent cohorts of pediatric T-ALL patients treated on DCOG
protocols (n  64)15 or the COALL-97 protocol (n  63).36 WT1
mutations were identified in 8 of 64 (12.5%) and 6 of 63 (9.5%)
patients treated on DCOG or COALL-97 protocols, respectively.
The disease-free survival at 5 years for the DCOG cohort was
62.5% plus or minus 17% versus 70% plus or minus 6% (log-rank:
P  .58) for WT1 mutated and wild-type patients, respectively,
whereas overall survival at 5 years was 62.5% plus or minus 17%
for WT1 mutated samples compared with 66% plus or minus 6%
for WT1-wild-type T-ALLs (log-rank: P  .74; Figure 3A). For the
COALL cohort, the 5-year disease-free survival for WT1 mutated
versus wild-type patients was 60% plus or minus 21% versus 78%
plus or minus 6% (log-rank: P  .29) and the 5-year overall
survival was 60% plus or minus 21% versus 70% plus or minus 8%
(log-rank: P  .54; Figure 3B). Given the higher prevalence of
WT1 mutations in T-ALL cases characterized by aberrant expres-
sion of TLX1/HOX11, TLX3/HOX11L2, and HOXA homeotic
transcription factor oncogenes, we analyzed the specific prognostic
significance of WT1 mutations in a group of 23 TLX3/HOX11L2-
positive T-ALLs. This analysis showed that the presence of WT1
mutations did not predict outcome in TLX3/HOX11L2 group. The
5-year disease-free survival for TLX3/HOX11L2-positive WT1-
mutant cases was 37.5% plus or minus 17% versus 56% plus or
minus 15% for TLX3/HOX11L2-positive WT1-wild-type T-ALLs
(log-rank: P  .29; Figure 3C).
Next we analyzed the effects of WT1 mutations on the survival
of 85 adult T-ALL patients treated in the MRC UKALLXII/
ECOGE2993 trial. WT1 mutations were present in 9 of 85 (10.5%)
T-ALL cases in this series. Complete remission was achieved in
76 of 85 (90%) of the patients, with no difference in therapy
response between WT1-wild-type and WT1-mutant samples in this
cohort (P  .65). Similarly, log-rank test analysis of overall
survival showed no difference between these 2 groups. Overall
survival at 2 years was 60% plus or minus 6% in WT1-wild-type
T-ALLs versus 56% plus or minus 17% in WT1 mutated cases
(P  .7; Figure 3D). Overall, these results support that, in contrast with
AML, WT1 mutations are not associated with poor prognosis in T-ALL.
Clonal evolution and disease relapse in T-ALL
Although analysis of clonality was not the primary aim of our
study, careful examination of the pattern of genetic alterations
observed in our SNP arrays and the pattern of concordance of
additional genetic markers such as NOTCH1 and WT1 mutations
and TCR rearrangements between diagnosis and relapse shows that
in 9 of 9 cases the relapsed clone shared at least one genetic marker
present in leukemic cells at diagnosis (Table 1, supplemental Table
Figure 3. Survival analysis of WT1 mutations in pediatric and adult T-ALL. (A-B) Kaplan-Meier plots of overall survival for pediatric T-ALL patients treated on DCOG (A)
and COALL-97 (B) protocols. (C) Kaplan-Meier plot of overall survival for TLX3 positive pediatric T-ALL patients. (D) Overall survival analysis in adult T-ALL patients treated in
the MRC UKALLXII/ECOG E2993 trial.
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5). However, we also noted that matched diagnostic and relapsed
samples were not identical and that most relapsed samples showed
the loss of at least one genetic marker present at diagnosis (Table 1,
supplemental Table 5). Acquisition of new chromosomal abnor-
malities and mutations at relapse was more limited, with only 3 of
9 samples showing the acquisition of new genetic lesions at relapse
(Table 1, supplemental Table 5). The model that emerges from
these data are that relapsed T-ALLs in our series did not
derive from the most predominant clone present at diagnosis,
but from an ancestral clone, which represents a related (shares
some genetic markers) but different (shows loss of genetic
markers and in some cases gain of new ones) subpopulation of
leukemic cells.
Discussion
Over the last 2 decades, the study of recurrent chromosomal
alterations has led to the identification of numerous oncogenes
and tumor suppressor genes involved in the pathogenesis of this
disease.37-39 More recently, the introduction of molecular cytoge-
netic techniques in the study of T-ALL has identified new
chromosomal rearrangements previously unrecognized using
standard cytogenetic assays.12,22,31,40-43 However, few studies
have addressed the mechanisms of disease progression leading
to relapse in T-ALL. Early studies on the role of TP53 in the
pathogenesis of T-ALL revealed TP53 mutations are rare in
T-ALL samples at diagnosis44,45 but can be found in approxi-
mately 30% of cases at relapse,45 suggesting TP53 inactivation
is selected in the leukemic clone as a mechanism to escape the
cytotoxic effects of chemotherapy. Given the safeguard function
of TP53 in preserving the integrity of the genome and the
mutagenic and genotoxic effects of chemotherapy, one could
predict that relapsed leukemias may be characterized by in-
creased genomic instability and harbor an increased number of
genetic mutations and chromosomal alterations. However, our
SNP array analysis comparing the pattern of chromosomal
alterations failed to detect a major increase in chromosomal
abnormalities at relapse, suggesting that spontaneous or chemo-
therapy-induced chromosomal instability may not be a major
mutagenic mechanism contributing to therapeutic failure.
After our identification via SNP array and FISH analysis of
chromosomal deletions in 11p13 encompassing the WT1 locus, we
have performed an extensive mutation analysis of the WT1 gene in
T-ALL. Our results demonstrate the presence of WT1 mutations in
approximately 10% of pediatric and adult T-ALL cases at diagno-
sis. Notably, previous reports have shown the absence of WT1
mutations in pre-B-ALL, suggesting that mutational loss of WT1
may contribute to transformation of T-cell and myeloid but not
B-cell progenitor cells.
Notably, 32 of 38 (84%) of the WT1 mutated T-ALL samples in
our series were heterozygous with integrity of the second WT1
allele. In addition, we failed to detect epigenetic inactivation of the
wild-type WT1 allele. Consistent with these results, allelic expres-
sion analysis in WT1-mutated T-ALLs demonstrated the presence
of both wild-type and mutant WT1 transcripts in T-ALL lympho-
blasts. Moreover, WT1 mutations found in T-ALL are typically
frameshift insertions and deletions predicted to encode C-terminal
truncated WT1 proteins devoid of DNA-binding activity. The
clustering of WT1 mutations in exon 7 could reflect some dominant-
negative effect of the resulting truncated WT1 protein products. In
this regard, one of the original papers on the characterization of
WT1 had already suggested that disruption of the DNA-binding
domain of WT1 could have a dominant-negative effect.46 More-
over, WT1 truncating mutations have been described as dominant-
negative alleles associated with the pathogenesis of the DDS.47
Nevertheless, the presence of associated deletions in the WT1-wild-
type allele in some of our cases suggests that WT1 mutations may
only have a partial dominant-negative effect.
Interestingly, WT1 mutations were particularly prevalent in
T-ALL cases harboring chromosomal rearrangements associated
with the expression of TLX1/HOX11, TLX2/HOX11L2, and HOXA9
transcription factor oncogenes, suggesting that WT1 loss and
aberrant expression of oncogenic homeobox factors may be
mechanistically linked in the pathogenesis of T-ALL.
Several studies have reported an association of WT1 mutations
with resistance to chemotherapy and poor prognosis in AML.7,34,35,48
However, we failed to detect any significant differences in response
to induction therapy and survival between WT1-mutated and
WT1-wild-type T-ALLs. This discrepant result suggests that WT1
mutations may confer different biologic properties to AML and
T-ALL lymphoblasts.
Finally, examination of the pattern of copy number alterations
from our SNP array analysis and additional genetic markers, such
as NOTCH1 and WT1 mutations and TCR rearrangements, showed
that most T-ALL cases at relapse are not the result of clonal
evolution from the predominant leukemic population present at
diagnosis. Thus, although all relapsed T-ALLs shared at least one
genetic marker with the predominant clone at diagnosis, they also
showed frequent loss of copy number alterations and mutations,
resulting in a genetically related but distinct disease. These results
are in agreement with those reported in an extensive study
analyzing the clonality of ALLs at diagnosis and relapse using SNP
array analysis.49 In that study, most ALLs revealed changes in the
pattern of alterations during disease progression. Thus, although
88% of ALLs shared genetic markers between the diagnosis and
relapse, 52% of the cases showed loss of at least one genetic
marker, demonstrating that clonal evolution from an ancestral
clone is a frequent mechanism associated with relapse in this
disease.49
In conclusion, our results identify the presence of WT1 muta-
tions as a recurrent genetic abnormality associated with aberrant
HOX gene expression in T-ALL.
Acknowledgments
This work was supported by the National Institutes of Health
(R01CA120196, R01CA129382, CA114737, and CA02111),
ECOG’s Leukemia Tissue Bank, the WOLF Foundation (A.A.F.),
the Leukemia & Lymphoma Society (grants 1287-08 and 6237-08;
A.A.F.), the Charlotte Geyer Foundation (A.A.F.), the Cancer
Research Institute (A.A.F.), the Swim Across America Foundation
(A.A.F.), the Golfers Against Cancer Foundation (A.A.F.), the
Leukemia Research Fund (R.E.G., D.C.L.), the Medical Research
Council of Great Britain (M.R.M.), and the Fondo de Investigacion
Sanitaria (grant CD07/00033; P.R.). A.A.F. is a Leukemia &
Lymphoma Society Scholar. T.P. is a recipient of a Young
Investigator Award from the Alex’s Lemonade Stand Foundation.
A complete list of the DCOG and the German COALL
participants can be found in the supplemental Appendix.
1044 TOSELLO et al BLOOD, 30 JULY 2009  VOLUME 114, NUMBER 5
 For personal use only. at COLUMBIA UNIV on January 28, 2010. www.bloodjournal.orgFrom 
Authorship
Contribution: V.T., M.R.M., K.B., M.P., M.L.S., S.J., C.G.A.,
R.E.G., T.P., P.R., and V.M. performed research; X.Y. and S.M.R.
performed statistical analysis; D.C.L., A.G., J.R., G.B., P.H.W.,
E.P., R.P., M.H., and J.P.P.M. provided samples and supervised
clinical studies; A.A.F. designed and supervised the study; and
A.A.F. and V.T. wrote the manuscript.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Adolfo A. Ferrando, Institute for Cancer
Genetics, Columbia University, 1130 St Nicholas Ave, Rm 505A,
New York, NY 10032; e-mail: af2196@columbia.edu.
References
1. Pui CH, Relling MV, Downing JR. Acute lympho-
blastic leukemia. N Engl J Med. 2004;350(15):
1535-1548.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic
leukaemia. Lancet. 2008;371(9617):1030-1043.
3. Bickmore WA, Porteous DJ, Christie S, et al. CpG
islands surround a D segment located between
translocation breakpoints associated with genito-
urinary dysplasia and aniridia. Genomics. 1989;
5(4):685-693.
4. Habib R, Loirat C, Gubler MC, et al. The nephrop-
athy associated with male pseudohermaphrodit-
ism and Wilm’s’ tumor (Drash syndrome): a dis-
tinctive glomerular lesion—report of 10 cases.
Clin Nephrol. 1985;24(6):269-278.
5. Haber DA, Buckler AJ, Glaser T, et al. An internal
deletion within an 11p13 zinc finger gene contrib-
utes to the development of Wilm’s’ tumor. Cell.
1990;61(7):1257-1269.
6. Carapeti M, Goldman JM, Cross NC. Dominant-
negative mutations of the Wilm’s’ tumour predis-
posing gene (WT1) are infrequent in CML blast
crisis and de novo acute leukaemia. Eur J
Haematol. 1997;58(5):346-349.
7. King-Underwood L, Pritchard-Jones K. Wilm’s’
tumor (WT1) gene mutations occur mainly in
acute myeloid leukemia and may confer drug re-
sistance. Blood. 1998;91(8):2961-2968.
8. King-Underwood L, Renshaw J, Pritchard-Jones
K. Mutations in the Wilm’s’ tumor gene WT1 in
leukemias. Blood. 1996;87(6):2171-2179.
9. Van Vlierberghe P, Homminga I, Zuurbier L, et al.
Cooperative genetic defects in TLX3 rearranged
pediatric T-ALL. Leukemia. 2008;22(4):762-770.
10. Palomero T, Barnes KC, Real PJ, et al. CUTLL1,
a novel human T-cell lymphoma cell line with
t(7;9) rearrangement, aberrant NOTCH1 activa-
tion and high sensitivity to gamma-secretase in-
hibitors. Leukemia. 2006;20(7):1279-1287.
11. Li C, Hung Wong W. Model-based analysis of oli-
gonucleotide arrays: model validation, design is-
sues and standard error application. Genome
Biol. 2001;2(8):RESEARCH0032.
12. Weng AP, Ferrando AA, Lee W, et al. Activating mu-
tations of NOTCH1 in human T cell acute lympho-
blastic leukemia. Science. 2004;306(5694):269-271.
13. Mansour MR, Duke V, Foroni L, et al. Notch-1
mutations are secondary events in some patients
with T-cell acute lymphoblastic leukemia. Clin
Cancer Res. 2007;13(23):6964-6969.
14. Thompson BJ, Buonamici S, Sulis ML, et al. The
SCFFBW7 ubiquitin ligase complex as a tumor
suppressor in T cell leukemia. J Exp Med. 2007;
204(8):1825-1835.
15. van Grotel M, Meijerink JP, Beverloo HB, et al.
The outcome of molecular-cytogenetic subgroups
in pediatric T-cell acute lymphoblastic leukemia: a
retrospective study of patients treated according
to DCOG or COALL protocols. Haematologica.
2006;91(9):1212-1221.
16. van Grotel M, Meijerink JP, van Wering ER, et al.
Prognostic significance of molecular-cytogenetic
abnormalities in pediatric T-ALL is not explained
by immunophenotypic differences. Leukemia.
2008;22(1):124-131.
17. Xiong Z, Laird PW. COBRA: a sensitive and
quantitative DNA methylation assay. Nucleic Ac-
ids Res. 1997;25(12):2532-2534.
18. Mullighan CG, Goorha S, Radtke I, et al. Genome-
wide analysis of genetic alterations in acute lympho-
blastic leukaemia. Nature. 2007;446(7137):758-764.
19. Kuiper RP, Schoenmakers EF, van Reijmersdal
SV, et al. High-resolution genomic profiling of
childhood ALL reveals novel recurrent genetic
lesions affecting pathways involved in lymphocyte
differentiation and cell cycle progression. Leuke-
mia. 2007;21(6):1258-1266.
20. Paulsson K, Cazier JB, Macdougall F, et al. Mi-
crodeletions are a general feature of adult and
adolescent acute lymphoblastic leukemia: unex-
pected similarities with pediatric disease. Proc
Natl Acad Sci U S A. 2008;105(18):6708-6713.
21. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a
tumour suppressor at the crossroads of cell divi-
sion, growth and differentiation. Nat Rev Cancer.
2008;8(2):83-93.
22. Graux C, Cools J, Melotte C, et al. Fusion of NUP214
toABL1 on amplified episomes in T-cell acute lympho-
blastic leukemia. Nat Genet. 2004;36(10):1084-1089.
23. Menke A, McInnes L, Hastie ND, Schedl A. The
Wilm’s’ tumor suppressor WT1: approaches to
gene function. Kidney Int. 1998;53(6):1512-1518.
24. Little M, Wells C. A clinical overview of WT1 gene
mutations. Hum Mutat. 1997;9(3):209-225.
25. Akasaka Y, Kikuchi H, Nagai T, Hiraoka N, Kato
S, Hata J. A point mutation found in the WT1
gene in a sporadic Wilm’s’ tumor without genito-
urinary abnormalities is identical with the most
frequent point mutation in Denys-Drash syn-
drome. FEBS Lett. 1993;317(1-2):39-43.
26. Little MH, Williamson KA, Mannens M, et al. Evi-
dence that WT1 mutations in Denys-Drash syn-
drome patients may act in a dominant-negative
fashion. Hum Mol Genet. 1993;2(3):259-264.
27. Sulis ML, Williams O, Palomero T, et al. NOTCH1
extracellular juxtamembrane expansion muta-
tions in T-ALL. Blood. 2008;112(3):733-740.
28. O’Neil J, Grim J, Strack P, et al. FBW7 mutations
in leukemic cells mediate NOTCH pathway acti-
vation and resistance to gamma-secretase inhibi-
tors. J Exp Med. 2007;204(8):1813-1824.
29. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/
hCDC4 is a general tumor suppressor in human can-
cer. Cancer Res. 2007;67(19):9006-9012.
30. Ferrando AA, Neuberg DS, Staunton J, et al.
Gene expression signatures define novel onco-
genic pathways in T cell acute lymphoblastic leu-
kemia. Cancer Cell. 2002;1(1):75-87.
31. Bernard OA, Busson-LeConiat M, Ballerini P, et
al. A new recurrent and specific cryptic transloca-
tion, t(5;14)(q35;q32), is associated with expres-
sion of the Hox11L2 gene in T acute lymphoblas-
tic leukemia. Leukemia. 2001;15(10):1495-1504.
32. Soulier J, Clappier E, Cayuela JM, et al. HOXA
genes are included in genetic and biologic net-
works defining human acute T-cell leukemia (T-
ALL). Blood. 2005;106(1):274-286.
33. Van Vlierberghe P, van Grotel M, Tchinda J, et al.
The recurrent SET-NUP214 fusion as a new HOXA
activation mechanism in pediatric T-cell acute lym-
phoblastic leukemia. Blood. 2008;111(9):4668-4680.
34. Virappane P, Gale R, Hills R, et al. Mutation of the
Wilm’s’ tumor 1 gene is a poor prognostic factor
associated with chemotherapy resistance in nor-
mal karyotype acute myeloid leukemia: the
United Kingdom Medical Research Council Adult
Leukaemia Working Party. J Clin Oncol. 2008;
26(33):5429-5435.
35. Paschka P, Marcucci G, Ruppert AS, et al. Wilm’s’
tumor 1 gene mutations independently predict poor
outcome in adults with cytogenetically normal acute
myeloid leukemia: a cancer and leukemia group B
study. J Clin Oncol. 2008;26(28):4595-4602.
36. Vieira Pinheiro JP, Wenner K, Escherich G, et al.
Serum asparaginase activities and asparagine
concentrations in the cerebrospinal fluid after a
single infusion of 2,500 IU/m(2) PEG asparagi-
nase in children with ALL treated according to
protocol COALL-06-97. Pediatr Blood Cancer.
2006;46(1):18-25.
37. Ferrando AA, Look AT. Clinical implications of re-
curring chromosomal and associated molecular
abnormalities in acute lymphoblastic leukemia.
Semin Hematol. 2000;37(4):381-395.
38. Aifantis I, Raetz E, Buonamici S. Molecular
pathogenesis of T-cell leukaemia and lymphoma.
Nat Rev Immunol. 2008;8(5):380-390.
39. O’Neil J, Look AT. Mechanisms of transcription
factor deregulation in lymphoid cell transforma-
tion. Oncogene. 2007;26(47):6838-6849.
40. Clappier E, Cuccuini W, Kalota A, et al. The C-
MYB locus is involved in chromosomal transloca-
tion and genomic duplications in human T-cell
acute leukemia (T-ALL), the translocation defin-
ing a new T-ALL subtype in very young children.
Blood. 2007;110(4):1251-1261.
41. Ellisen LW, Bird J, West DC, et al. TAN-1, the hu-
man homolog of the Drosophila notch gene, is
broken by chromosomal translocations in T lym-
phoblastic neoplasms. Cell. 1991;66(4):649-661.
42. Lahortiga I, De Keersmaecker K, Van Vlierberghe
P, et al. Duplication of the MYB oncogene in T cell
acute lymphoblastic leukemia. Nat Genet. 2007;
39(5):593-595.
43. O’Neil J, Tchinda J, Gutierrez A, et al. Alu elements
mediate MYB gene tandem duplication in human
T-ALL. J Exp Med. 2007;204(13):3059-3066.
44. Gump J, McGavran L, Wei Q, Hunger SP. Analy-
sis of TP53 mutations in relapsed childhood acute
lymphoblastic leukemia. J Pediatr Hematol On-
col. 2001;23(7):416-419.
45. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M. Non-
hereditary p53 mutations in T-cell acute lympho-
blastic leukemia are associated with the relapse
phase. Blood. 1994;83(10):2922-2930.
46. Haber DA, Timmers HT, Pelletier J, Sharp PA,
Housman DE. A dominant mutation in the Wilm’s
tumor gene WT1 cooperates with the viral oncogene
E1A in transformation of primary kidney cells. Proc
Natl Acad Sci U S A. 1992;89(13):6010-6014.
47. Little M, Holmes G, Bickmore W, van Heyningen
V, Hastie N, Wainwright B. DNA binding capacity
of the WT1 protein is abolished by Denys-Drash
syndrome WT1 point mutations. Hum Mol Genet.
1995;4(3):351-358.
48. Summers K, Stevens J, Kakkas I, et al. Wilm’s’
tumour 1 mutations are associated with FLT3-ITD
and failure of standard induction chemotherapy in
patients with normal karyotype AML. Leukemia.
2007;21(3):550-551; author reply 552.
49. Mullighan CG, Phillips LA, Su X, et al. Genomic
analysis of the clonal origins of relapsed acute
lymphoblastic leukemia. Science. 2008;
322(5906):1377-1380.
WT1 MUTATIONS IN T-ALL 1045BLOOD, 30 JULY 2009  VOLUME 114, NUMBER 5
 For personal use only. at COLUMBIA UNIV on January 28, 2010. www.bloodjournal.orgFrom 
